RaQualia Pharma Inc. (TYO:4579)

Japan flag Japan · Delayed Price · Currency is JPY
763.00
-26.00 (-3.30%)
May 12, 2026, 3:30 PM JST
Market Cap19.86B +142.7%
Revenue (ttm)3.98B +28.1%
Net Income273.00M
EPS11.36
Shares Out26.03M
PE Ratio67.17
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume162,500
Average Volume139,550
Open794.00
Previous Close789.00
Day's Range761.00 - 796.00
52-Week Range418.00 - 1,465.00
Beta0.94
RSI36.82
Earnings DateMay 15, 2026

About RaQualia Pharma

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 85
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4579
Full Company Profile

Financial Performance

Financial Statements